Five studies assessed levels of IL-4 in patients with AD (Table 1), with significant reductions observed in intervention groups of Prakoeswa et al. [61] and Prakoeswa et al. [39], (Δ = 6.007, intervention; Δ = 4.197, placebo, p = 0.000, Δ = 2.906, intervention; Δ = 0.651, placebo, p < 0.05), respectively. This evidence concerns the gene IL4 and Alzheimer disease.